comparemela.com

Page 2 - Society Of Urologic Oncology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ASCO 2024: Camrelizumab plus Apatinib for Previously Treated Advanced Adrenocortical Carcinoma: A Single-Arm, Open-Label, Phase 2 Trial

ASCO 2024:A Multi-Institution Analysis of Outcomes With First-Line Systemic Therapy for 102 Patients With Metastatic Chromophobe Renal Cell Carcinoma

ASCO 2024: Advanced Sequencing and Targeted Therapy Strategies in Renal Cell Carcinoma: How Can We Help More Patients Not at the Expense of Toxicity?

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.